← All funded startups

August 11, 2026

Epicrispr

Epicrispr is a San Francisco-based company developing programmable epigenetic medicines.

Round: Series C
Amount raised: $90M
Lead investor: Octagon Capital
Industry: Biotechnology
Headquarters: San Francisco, United States
Employees: —
Website: —
LinkedIn: —

Other investors

Janus Henderson Investors
Fidelity
Cormorant Asset Management
Duquesne Family Office
Sanofi Ventures
Abrdn
Angelini Ventures
Readout Capital

Source: Axios Pro Rata